Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.42 |
| ▸ | HRH1 | P35367 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154130 | 0.94 | MAOB (0.43) | MAOBCYP2D6HRH1KCNH2CHRM1 | |
| SCHEMBL4142025 | 0.94 | MAOB (0.42) | MAOBCYP2D6HRH1KCNH2CHRM1 | |
| SCHEMBL4153083 | 0.90 | CCR3 (0.43) | CYP2D6HRH1KCNH2CHRM1 | |
| SCHEMBL4147399 | 0.88 | MAOB (0.46) | MAOBKCNH2DRD4SLC6A4SLC6A3 | |
| SCHEMBL4152281 | 0.85 | CYP2D6 (0.53) | MAOBCYP2D6HRH1KCNH2CHRM1 | |
| SCHEMBL4139579 | 0.83 | CYP2D6 (0.43) | MAOBCYP2D6DRD4SLC6A4SLC6A3 | |
| SCHEMBL4154027 | 0.80 | CYP2D6 (0.52) | MAOBCYP2D6HRH1KCNH2CHRM1 | |
| SCHEMBL4139191 | 0.79 | GRM2 (0.55) | CYP2D6HRH1KCNH2CHRM1DRD4 | |
| SCHEMBL4162777 | 0.76 | SLC6A4 (0.42) | SLC6A4SLC6A3 | |
| SCHEMBL4151656 | 0.76 | GRM2 (0.57) | DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | claimed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | MAOB 1025/4885CYP2D6 1251/4885HRH1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.